Martec Pharmaceutical
Executive Summary
Parent Kansas City Southern Industries sold 51% controlling interest to West German firm Ratiopharm GmbH on March 22 for an undisclosed sum. Deal marks Ratiopharm's first U.S. drug company purchase. KCSI said divestiture of its largest pharmaceutical business was in line with previously announced plans to restructure that segment of its operations. KCSI retains 49% interest in Martec. Martec exec John Wilcox named president.